Aurinia Pharmaceuticals(AUPH) ZACKS·2025-01-22 18:00Core Viewpoint - Aurinia Pharmaceuticals (AUPH) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive earnings outlook that may lead to increased stock price [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with stock price movements [4][6]. - Aurinia is projected to earn $0.05 per share for the fiscal year ending December 2024, reflecting a year-over-year increase of 109.3% [8]. - Over the past three months, the Zacks Consensus Estimate for Aurinia has risen by 23.9% [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a 'Strong Buy' or 'Buy' rating [9][10]. - The upgrade of Aurinia to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].